These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 12621741)
1. [Investigation on administration method of carbapenems]. Mikamo H; Ninomiya M; Tamaya T Jpn J Antibiot; 2002 Dec; 55(6):875-81. PubMed ID: 12621741 [TBL] [Abstract][Full Text] [Related]
2. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549 [TBL] [Abstract][Full Text] [Related]
4. [Proper use of carbapenem antibiotics based on the feature in the treatment of infectious diseases (discussion)]]. Kaku M; Inoue M; Sagawa K; Nasu M; Yokoyama T Jpn J Antibiot; 2004 Feb; 57(1):1-10. PubMed ID: 15116571 [No Abstract] [Full Text] [Related]
5. [Antibacterial activity of biapenem against recent clinical isolates]. Hara T; Araake M; Watabe H Jpn J Antibiot; 2003 Apr; 56(2):138-41. PubMed ID: 12825414 [TBL] [Abstract][Full Text] [Related]
6. Overview of a new carbapenem, panipenem/betamipron. Shimada J; Kawahara Y Drugs Exp Clin Res; 1994; 20(6):241-5. PubMed ID: 7758396 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia. Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863 [TBL] [Abstract][Full Text] [Related]
8. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A; J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280 [TBL] [Abstract][Full Text] [Related]
10. [In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA]. Sato S; Miura T; Kudo E; Kudo Y; Saitoh Y; Kimpara I; Tsujino M; Kudo H Jpn J Antibiot; 1997 Aug; 50(8):711-6. PubMed ID: 9339397 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Kotapati S; Kuti JL; Nicolau DP Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939 [TBL] [Abstract][Full Text] [Related]
12. [In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae]. Fukuoka T; Inoue H; Abe T; Ohya S Jpn J Antibiot; 2001 Jul; 54(7):365-71. PubMed ID: 11560055 [TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. Kurihara A; Hisaoka M; Mikuni N; Kamoshida K J Pharmacobiodyn; 1992 Jul; 15(7):325-32. PubMed ID: 1447679 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Lomaestro BM; Drusano GL Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. Katsube T; Yamano Y; Yano Y J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288 [TBL] [Abstract][Full Text] [Related]
16. The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa. Harashima S; Kondo H; Nabeshima A; Shimoda M; Yamaji K; Horiuchi T; Shimono N; Ikematsu H J Infect Chemother; 2008 Jun; 14(3):219-22. PubMed ID: 18574658 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen. Ishihara N; Nishimura N; Tamaki H; Karino F; Miura K; Isobe T; Ikawa K; Morikawa N; Naora K Int J Clin Pharmacol Ther; 2015 Jun; 53(6):422-9. PubMed ID: 25828635 [TBL] [Abstract][Full Text] [Related]
18. Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia. Giamarellos-Bourboulis EJ; Mega A; Pavleas I; Archontoulis N; Rigas K; Vernikos P; Giamarellou H; Thomopoulos G J Chemother; 2006 Oct; 18(5):502-6. PubMed ID: 17127227 [TBL] [Abstract][Full Text] [Related]
19. Changing role of carbapenems in the treatment of lower respiratory tract infections. Lode H; Hamacher J; Eller J; Schaberg T Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Ong CT; Kuti JL; Nicolau DP; Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]